Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk. [PDF]
Front ImmunolVahldieck C, Fels B.
europepmc +1 more source
Time-Related Burden of Treatment With Parenterally Administered Complement Inhibitors: A Mixed Methods Observational Study Exploring Experiences among Patients With Paroxysmal Nocturnal Hemoglobinuria. [PDF]
Health Sci RepDingli D +11 more
europepmc +1 more source
Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder. [PDF]
Case Rep Neurol MedTsuzaki K +5 more
europepmc +1 more source
Meningococcemia in a Boy with Dense Deposit Disease Receiving the C5 Complement Inhibitor Ravulizumab: A Case Report. [PDF]
Clin Pract Cases Emerg MedGonedes AJ +4 more
europepmc +1 more source
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry. [PDF]
Am J HematolRöth A +8 more
europepmc +1 more source
Complement C5 inhibitors as add-on rescue treatment in severe AQP4-antibody neuromyelitis optica spectrum disorder attacks: a case series and literature review. [PDF]
Ther Adv Neurol DisordGan KX +5 more
europepmc +1 more source
Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review. [PDF]
J Clin MedGandhi S +6 more
europepmc +1 more source
Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review. [PDF]
Front PharmacolZhang D, Xiao Y, Ma H.
europepmc +1 more source
Ravulizumab in IgA Nephropathy
Journal of the American Society of NephrologyGao, Youyuan, Huang, Yunjian
openaire +4 more sources
Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database. [PDF]
PLoS OnePeffault de Latour R +7 more
europepmc +1 more source